

Lysis
Apoptosis
2 Tumor Cell
1 T-Cell
CTLA-4
PD-1
TAA
CD3
CD40L / CD28 /CD69
(Activation Marker)
1 Sustained T-cell activation
2 Enhanced Tumor cell destruction
Multispecific T-cell redirecting antibody
Checkpoint inhibitor blocking antibody

Figure 1



CD69
CTLA4
CD4 + T-cells
CD8+ T-cells
CD4+ T-cells
CD8+ T-cells
without Surek
+ Surek (1µg/ml)
time in h
0
24
48
72
20
40
60
80
100
10
30

Figure 2





Figure 2 continued


A
100
80
60
40
20
0
% survival
0
30
60
90
120
A: control
B: HB304
days after tumor challenge (B78-D14)



B
100
80
60
40
20
0
% survival
0
20
40
60
80
100
120
A (Surek)
B (Surek + HB304)
C (control)
days after tumor challenge (B78-D14)

Figure 3



100
80
60
40
20
0
% survival
0
30
60
90
120
150
days after tumor challenge (B16-EpCAM)
A: control
B: BiLu
C: BiLu + HB304
D: HB304

Figure 4